Background: Both thermotherapy and arsenic have been shown to be active against a broad spectrum of cancers. To reduce the limitations of conventional thermotherapy, improve therapeutic anticancer activity, reduce the toxicity of arsenic on normal tissue, and increase tissuespecific delivery, we prepared a nanosized As 2 O 3 /Fe 3 O 4 complex (Fe 3 O 4 magnetic nanoparticles encapsulated in As 2 O 3 ). We assessed the thermodynamic characteristics of this complex and validated the hyperthermia effect, when combined with magnetic fluid hyperthermia (MFH), on xenograft HeLa cells (human cervical cancer cell line) in nude mice. We also measured the effect on the expression of CD44v6, VEGF-C, and MMP-9 which were related to cancer and/or metastasis.
which has many limitations. With the development of nanotechnology, magnetic nanoparticles have been used not only as drug carriers but also in tumor hyperthermia, as such particles absorb energy from high frequency AMF. Nanoscaled magnetic fluid has been found to absorb much more energy than conventional materials, and this energy is further transferred to tumor cells resulting in tumor temperatures of 42°C-45°C. This process, termed "Magnetic Fluid Hyperthermia (MFH)" can be used for the treatment of either non-cancer diseases or tumors [1] . Magnetic nanoparticles may be good thermoseeds for localized hyperthermia treatment of cancers [2] , permitting the heating of and damage to normal tissue to be avoided, thus overcoming the limitations of conventional heat treatment. Fe 2 O 3 magnetic nanoparticles used in MFH were reported to have a significant therapeutic effect on xenograft liver cancer in nude mice [3] . Depending on the applied temperature and the duration of heating this treatment either results in direct tumor cell killing or makes the cells more susceptible to concomitant radio-or chemotherapy. Numerous groups are working in this field worldwide, but only one approach has been tested in clinical trials so far.
Metastatic spread of the solid tumor depends on a critical cascade of events, which includes tumor cell adhesion to a distant site, extracellular matrix degradation, migration, proliferation, and ultimately neovascularization. Tumors that produce higher levels of metastasis-related factors, such as proteins encoded by the "cluster of differentiation 44v6" (CD44v6) gene, and the genes encoding vascular endothelial growth factor-C (VEGF-C) and matrix metalloproteinase-9 (MMP-9), may show more aggressive behavior than do tumors negative for these factors. Thus, a treatment that could inhibit the expression of these tumor metastasis-related factors would be of great interest.
Arsenic is a well-documented carcinogen that also appears to be a valuable therapeutic tool in cancer treatment [4] . The first use of As 2 O 3 in cancer therapy was to treat acute promyelocytic leukemia (APL) [5] . The results of in vitro research and clinical trials have shown that As 2 O 3 is effective in inhibiting tumor growth, and in inducing the differentiation and apoptosis of APL cells. Because of its significant anti-cancer effects, As 2 O 3 has been tested in patients with other tumor types, including gastric cancer [6] , neuroblastoma [7] , esophageal carcinoma [8] , and head and neck cancers [9] . Moreover, As 2 O 3 was shown to inhibit tumor metastasis by reducing the expression of metastasis-related genes [10] [11] [12] .
The purpose of this study was to prepare nanosized As 2 O 3 /Fe 3 O 4 complex for tumor thermochemotherapy and validate its effect on xenograft tumor in nude mice as a premature treatment. We also tested the ability of a nanosized As 2 O 3 /Fe 3 O 4 complex combined with MFH to inhibit the expression of metastasis-associated genes.
Methods

Reagents
As 2 O 3 was purchased from Sigma (St Louis, MO; Lot A1010). A 1 mM stock solution in RMPI 1640 medium (Gibco) was prepared, stored at 0-4°C, and diluted before use. Calf serum from newborn animals was obtained from Si-Ji-Qing Biotechnology Co. (Hangzhou, China). HEPES (the free acid) and trypsin were obtained from Amresco Corp. RNAiso reagent, AMV retroviridase, dNTPs, Oligo(dT)18, Taq DNA polymerase, and DNA markers were purchased from Takara Biotechnology Co. (Dalian, China). VEGF-C, CD44v6, and MMP-9 primers were obtained from Shen-neng-bo-cai Biotechnology (Shanghai, China). magnetic nanoparticles were added to a solution of As 2 O 3 (0.01 mg/mL, pH = 5, adjusted with acetic acid) with sonication. After 30 min of thermal treatment at 80°C, the resulting nanosized As 2 O 3 /Fe 3 O 4 complex was centrifuged at 2,000 g/ min for 10 min, rinsed twice with absolute ethanol, and dried under vacuo. The diameter of the nanosized As 2 O 3 / Fe 3 O 4 complex particles was measured by transmission electron microscopy (TEM; Hitachi H-600 instrument; Japan).
Preparation of the Nanosized
Heat Testing of Nanosized As 2 O 3 /Fe 3 O 4 Complex in Vitro
The nanosized As2O3/Fe3O4 complex was dispersed in 0.9% (w/v) NaCl, at Fe3O4 concentrations of 0.5, 1.0, 1.5, 2.0 and 2.5 mg/mL, and 2 mL aliquots of magnetic fluids were added to flat-bottomed cuvettes and placed in a high frequency electromagnetic field. The distance from the bottom of the cuvette to the center of the source (coils) of the high frequency field was 5 mm. The output frequency was 230 kHz and the output current 20 A. Throughout 1 h of incubation, the temperature was measured every 5 min.
Cell Culture
HeLa cells (a human cervical cancer cell line, provided by the Institute of Biochemistry and Cell Biology, Shanghai Institute of Biological Sciences, Chinese Academy of Sciences) were maintained in RPMI-1640 medium supplemented with 10% (v/v) heat-inactivated fetal calf serum, 100 units/mL penicillin, and 100 mg/L streptomycin, at 37°C in a 5% CO 2 /95% air (v/v) incubator under 95% relative humidity.
Animal Experiments
Female BALB/C nude mice, aged 6 weeks, were purchased from the Lakes Animal Experimental Center of the Institute of Biochemistry and Cell Biology, Shanghai Institute of Biological Sciences, China. The animal experiments were approved by the regional animal ethics committee and the mice treated in accordance with the international animal ethics guidelines. All of the mice were maintained in the animal facility of School of Basic Medical Sciences, Southeast University, China. Mice were housed up to 8 animals per cage in individual ventilation cages and fed with specific pathogen-free mice chow ad libitum. Exponentially growing HeLa cells (density >10 5 cells/mL) were injected subcutaneously around the right posterior limb rump. When tumor diameters reached 0.5 cm, mice were divided into four groups of eight mice each: (1) sterile 0.9% (w/v) NaCl (control group), (2) 5 μM As 2 O 3 dispersed in 0.9% (w/v) NaCl (As 2 O 3 group), (3) 1 mg/mL of Fe 3 O 4 dispersed in 0.9% (w/v) NaCl (Fe 3 O 4 group), and (4) 1 mg/mL of Fe 3 O 4 and 5 μM As 2 O 3 dispersed in 0.9% (w/v) NaCl (As 2 O 3 /Fe 3 O 4 group). The solution/suspension (1, 2, 3, or 4) were directly injected into tumors with a volume equal to half the tumor volume. In our study, we applied the method of multipoint injection, following clockwise, at the 3, 6, 9, and 12 o'clock points. The tumors of the Fe 3 O 4 and As 2 O 3 /Fe 3 O 4 groups were exposed to high frequency AMF (f = 230 kHz, I = 20 A) for 30 min, three times at 24 h intervals [13] . Tumor temperature was measured at multipoint using an infrared thermometer (ZyTemp-TN18 model; China). Mice were sacrificed after 6 weeks, and the mass and volume of each tumor were measured. Tumor growth inhibition was evaluated by measuring mass and volume inhibition proportions. Mass inhibition (IM) was calculated as (1 -Relative tumor mass) × 100%, where relative tumor mass (RTM) was the mean tumor mass of the experimental group divided by the mean tumor mass of the control group. Similarly, volume inhibition (IV) was calculated as (1 -Relative tumor volume) × 100%, where relative tumor volume (RTV) was the mean tumor volume of the experimental group divided by the mean tumor volume of the control group. 
Expression of CD44V6, VEGF-C, and MMP-9 after Thermochemotherapy of HeLa cells In vitro treatment and sampling
RNA isolation
RNA was extracted from cells using the RNAiso reagent, according to the supplier's protocol. The purity and concentration of RNA were determined by spectrophotometry at 260 nm. The quality of RNA was checked by electrophoresis of 2-3 μL samples in 1% (w/v) agarose gels, staining with ethidium bromide, and examining the 28S and 18S rRNA bands under UV light. No significant degradation was observed in any RNA sample.
Semi-quantitative reverse transcription polymerase chainreaction (RT-PCR)
Total RNA was denaturated for 10 min at 70°C. Each RT reaction (20 μL volume) contained 2 μL of total RNA,1 μL of Oligo dT18, 2 μL of each dNTP (10 mM), 0.5 μL RNasin, 1 μL AMV retroviridase, 4 μL 5 × AMV buffer, and 9.5 μL of DEPC water. Each reaction mixture was incubated for 1 hour at 42°C, and the reverse transcriptase was inactivated by heating at 95°C for 5 min. Each cDNA product was frozen at -20°C until use.
PCR reactions were performed in 25 μL volumes containing 5 μL cDNA, 2 μL 10× PCR buffer, 2 μL dNTP (2.5 mM), 1 μL sense primers, and 1 μL antisense primers [14] [15] [16] (20 pmol/μL, please see Table 1 ; β-actin primers were used as an internal control), 0.5 μL Taq DNA polymerase (5 U/μL), 2.5 μL MgCl 2 (25 mM), and 11 μL DEPC water. After initial denaturation at 96°C for 3 min, the mixtures were subjected to a varying number of denaturation cycles (each at 1 min at 94°C), annealing (1 min at 56°C for β-actin; 57°C for VEGF-C; and 60°C for other genes) and extension (2 min at 72°C), and a final extension at 72°C for 10 min, in a PTC-100 thermal cycler (MJ Research, Watertown, MA). Samples were stored at -20°C. For each reaction, a negative control employed distilled water instead of cDNA, and cDNA from untreated HeLa cells served as the positive control. Figure 6 , Table 3 ).
Results
Characteristics of the
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Discussion
Heat therapies such as hyperthermia and thermoablation are very promising approaches in the treatment of cancer. Compared with available hyperthermia modalities, MFH yields better results in uniform heating of the deeply situated tumors. In this approach, fluid consisting of superparamagnetic nanoparticles (magnetic fluid) is delivered to the tumor. An AMF is then used to heat the particles and the corresponding tumor, thereby ablating it [18] . Interstitial hyperthermia following direct injection of nanoparticles has also been proven successful in many animal models. Jordan A et al. reported good effects of MFH on C3H mammary carcinoma in vivo [19] . A variety of magnetic fluids have been applied using related techniques (differing mostly in the formulation of the nanoparticles), but so far only few of these approaches has been successfully translated from research to clinical stage.
All magnetic nanoparticles used so far in vivo are composed of the iron oxides magnetite ( Table 2 and Figure 4 , although the tumor inhibition appears to be primarily due to the heat, we can still see that the combination was more effective than either Fe 3 O 4 magnetic nanoparticles plus MFH, or As 2 O 3 treatment alone. In addition, the heat created during thermotherapy may directly damage tumor cells or may make cells more susceptible to accompanying chemotherapy [21] .
MFH has been undergoing clinical testing. In three clinical studies the safety and the feasibility of the technique has been proven. In March 2003, the first clinical feasibility study on magnetic nanoparticle hyperthermia was started with 14 patients suffering from glioblastoma multiforme [22] . All patients received a neuro-navigationally guided injection of the magnetic fluid into the tumor. The amount of fluid and the spatial distribution of the depots were planned in advance by means of a specially developed treatment planning software following magnetic resonance imaging (MRI). The actually achieved magnetic fluid distribution was measured by computed tomography (CT).
In prostate cancer, a direct injection technique of MFH was investigated in phase-I-study. The feasibility and good tolerability was shown in the trial [23, 24] . This novel approach requires specific tools for planning, quality control and thermal monitoring, based on appropriate imaging and modelling techniques. Treatment planning was carried out using CT of the prostate. Nanoparticle suspensions were injected transperineally into the prostate under transrectal ultrasound and flouroscopy guidance.
Another prospective feasibility study enrolled 22 patients with proven recurrences and residual tumors (non-resectable and pre-treated, e.g. prostate and cervix carcinoma, soft tissue sarcoma) [25] . Three implantation methods were established: Infiltration under CT fluoroscopy (group A), TRUS (transrectal ultrasound)--guided implantation with X-fluoroscopy (group B) and intra-operative infiltration under visual control (group C). In group A and B the distribution of the nanoparticles can be planned prior to implantation on the basis of three-dimensional image datasets. These approaches of MFH above were well tolerated by patients.
MFH is suitable for treatment of superficial tumors by direct injection of nanoparticle suspension, which was first reported in 1997 [19] . For deep tumors, the feasibility and good tolerability of different injection techniques (CT, ultrasound or X-fluoroscopy guided) were shown. Endoscope such as Oesophagoscope and vaginoscope can be respectively used as guiding devices for esophageal cancer and cervical cancer. A different approach of using magnetic nanoparticles for heating tumor cells is termed ferromagnetic embolization hyperthermia. This technique, which uses a feeding artery to carry nanoparticles into the tumor, seems to be especially well suited for the treatment of hepatic malignancies due to the differences in blood supply between hepatic tumor cells and normal liver parenchyma. Several preclinical studies on arterial embolization hyperthermia of liver cancer were reported [26] [27] [28] , and Granov reported this treatment on clinical use [29] .
Metastasis, a unique characteristic of malignant tumors, is the most difficult issue in the clinical treatment of cancer and the major cause of death. Hyperthermia may trigger immune responses that inhibit the metastasis of graft tumors [30] .
"Cluster of differentiation 44" (CD44) is a cell surface adhesion molecule that recognizes hyaluronate and mediates diverse functions, such as cell-cell and cell-matrix adhesion, lymphocyte homing, and T-cell adhesion and activation. CD44 exists as a standard form (CD44s) and as multiple isoforms, each generated by alternative splicing of up to 10 variant exons encoding parts of the extracellular domain. CD44, especially the CD44v6 variant, has a role in tumor progression and metastasis in human cancers [31] . Expression of CD44v6 has been found to corre- In the vascular endothelial growth factor (VEGF) family, VEGF-C is a ligand for VEGF receptor (VEGFR)-3, a tyrosine kinase receptor that is predominantly expressed in the endothelium of lymphatic vessels. VEGF-C plays an important role in tumor metastasis by mediating the formation of lymphatic vessels. Most cancer cells express VEGF-C, and such expression positively correlates with tumor angiogenesis and metastasis [33] . As 2 O 3 has been reported to inhibit VEGF expression, preventing the proliferation, invasion, and metastasis of solid tumors [34] . In addition, expression of VEGF mRNA and protein by fibrosarcomas was significantly inhibited after thermotherapy at 42°C [35] . Moreover, the density of tumor vessels in gliomas was reduced after thermotherapy and even more after thermochemotherapy, indicating that thermo- CD44v6 0.386 ± 0.049 0.396 ± 0.052 0.438 ± 0.115 0.210 ± 0.075 (1) 0.244 ± 0.120 (1) 0.142 ± 0.064 (1)(2) 0.117 ± 0.030 (1)(3) VEGF-C 0.605 ± 0.166 0.514 ± 0.083 0.398 ± 0.079 (1) 0.305 ± 0.132 (1)(2) 0.344 ± 0.038 (1) 0.095 ± 0.016 (1) 
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Expression of (A) CD44v6, (B) VEGF-C, and (C) MMP-9 mRNA after treatment of HeLa cells therapy may inhibit the expression of VEGF mRNA and protein [36] .
Matrix metalloproteinases (MMPs) are a family of zincand calcium-dependent enzymes that degrade extracellular matrix proteins, such as laminin, fibronectin, and collagen. MMPs mediate the invasive properties of most malignant cells and promote angiogenesis through their ability to degrade basement membranes and to remodel extracellular matrix architecture. In particular, MMP-9 specifically degrades collagen IV, the major component of the basement membrane. Expression of MMP-9 has been found to correlate with tumor invasiveness and metastasis, including lymph node metastasis [37] . As 2 O 3 reduced the expression of MMP-9 by nasopharyngeal carcinoma cells in vitro, and decreased their invasive and metastatic properties [12] . Using As 2 O 3 /Fe 3 O 4 nanoparticles, we found that As 2 O 3 dose-dependently inhibited the expression of CD44v6, VEGF-C, and MMP-9 mRNA. Moreover, thermotherapy alone inhibited the expression of VEGF-C mRNA to some extent.
Conclusion
The nanosized As 2 O 3 /Fe 3 O 4 complexes described here possess not only the chemotherapeutic activity of As 2 O 3 but also the characteristic of strong magnetic responsiveness arising from the presence of Fe 3 O 4 . These particles are suitable for treating superficial tumors by direct injection and for deep tumors by using different injection techniques (CT, ultrasound or X-fluoroscopy guided, intraoperatively under visual control), because they absorb energy from high frequency AMF and also have chemotherapeutic effects. For early stage tumors, thermochemotherapy of nanosized As 2 O 3 /Fe 3 O 4 complexes could be used as preoperative treatment because of reducing tumor volume and intraoperative bleeding, creating better conditions for latter surgery. In addition, it may be can inhibit tumor metastasis to some extent.
Most researches of MFH in this field applied so far have only been evaluated in preclinical studies. In spite of some Phase I trials have been carried out, it is still too early to claim therapeutic advantages for the applied method because survival benefit or time to progression were not defined endpoints of the finished feasibility studies. However, the ongoing Phase II trials will provide an initial indication whether MFH can improve survival and/or quality of life. 
